You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Granulocyte-macrophage colony stimulating factor (GM-CSF)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroblastoma Trial (Naxitamab)

Not yet recruiting
  • Neuroblastoma
  • (no location specified)
Sep 18, 2023

Recurrent Osteosarcoma Trial in Los Angeles, New York, Houston (humanized anti-GD2 antibody, GM-CSF)

Recruiting
  • Recurrent Osteosarcoma
  • humanized anti-GD2 antibody
  • GM-CSF
  • Los Angeles, California
  • +2 more
Dec 22, 2022

Neuroblastoma Trial in New York (Hu3F8 With GM-CSF)

Active, not recruiting
  • Neuroblastoma
  • Hu3F8 With GM-CSF
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 2, 2022

Renal Cancer Trial in Boston (Dendritic Cell Tumor Fusion Vaccine, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF))

Active, not recruiting
Has Results
  • Renal Cancer
  • Dendritic Cell Tumor Fusion Vaccine
  • Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
  • Boston, Massachusetts
    Beth Israel Deaconess Medical Center
Jan 2, 2023

Breast Cancer Trial in Boston (Autologous, Lethally Irradiated Breast Cancer Cells)

Completed
Has Results
  • Breast Cancer
  • Autologous, Lethally Irradiated Breast Cancer Cells
  • Boston, Massachusetts
  • +1 more
Mar 30, 2022

Lymphoma, Non-Hodgkin, HIV Trial in Los Angeles (Bleomycin sulfate, Vincristine sulfate, Doxorubicin HCl)

Completed
  • Lymphoma, Non-Hodgkin
  • HIV Infections
  • Bleomycin sulfate
  • +8 more
  • Los Angeles, California
    USC CRS
Oct 26, 2021

Chronic Myeloproliferative Disorders, GVHD, Leukemia Trial in Buffalo (sargramostim)

Completed
  • Chronic Myeloproliferative Disorders
  • +5 more
  • sargramostim
  • Buffalo, New York
    Roswell Park Cancer Institute
Oct 3, 2022

Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)

Recruiting
  • Neuroblastoma
  • Naxitamab monotherapy
  • +6 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 31, 2023

IVF, PCOS, IVM Trial in Ho Chi Minh City (GM-CSF group, Control group)

Recruiting
  • IVF
  • +2 more
  • GM-CSF group
  • Control group
  • Ho Chi Minh City, Vietnam
    My Duc Hospital
Jul 12, 2021

Severe Acute Respiratory Syndrome (SARS) Pneumonia, COVID-19 Pneumonia Trial in Germany (Molgramostim nebuliser solution,

Active, not recruiting
  • Severe Acute Respiratory Syndrome (SARS) Pneumonia
  • COVID-19 Pneumonia
  • Molgramostim nebuliser solution
  • Placebo nebuliser solution
  • Dresden, Germany
  • +8 more
Jun 20, 2022

Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial in Boston (GM-CSF, Dendritic Cell/Tumor Fusion Vaccine,

Active, not recruiting
  • Ovarian Cancer
  • +2 more
  • Boston, Massachusetts
  • +3 more
Jan 25, 2022

Hepatitis B, Chronic Trial in Beijing (Granulocyte Macrophage-colony Stimulating Factor, Entecavir)

Terminated
  • Hepatitis B, Chronic
  • Granulocyte Macrophage-colony Stimulating Factor
  • Entecavir
  • Beijing, Beijing, China
    302 Military Hospital
Mar 9, 2022

Thymoma Trial in Shanghai (Radiotherapy Combined with GM-CSF)

Recruiting
  • Thymoma
  • Radiotherapy Combined with GM-CSF
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 2, 2022

Breast Ductal Carcinoma In Situ Trial in Jacksonville, Rochester (Granulocyte-Macrophage Colony-Stimulating Factor,

Recruiting
  • Breast Ductal Carcinoma In Situ
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • +2 more
  • Jacksonville, Florida
  • +1 more
Dec 10, 2021

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023

Down Syndrome Trial in Aurora (Sargramostim for Injection, Saline Placebo)

Not yet recruiting
  • Down Syndrome
  • Sargramostim for Injection
  • Saline Placebo
  • Aurora, Colorado
    University of Colorado Anschutz Medical Campus
Jul 28, 2022

ARDS Trial in Germany (inhaled molgramostim (rhGM-CSF), inhaled )

Active, not recruiting
  • ARDS
  • inhaled molgramostim (rhGM-CSF)
  • inhaled placebo
  • Würzburg, Baden-Würtemberg, Germany
  • +6 more
Oct 27, 2021

HIV Trial in United States (APL 400-047, ALVAC-HIV MN120TMG (vCP205), Sargramostim)

Completed
  • HIV Infections
  • APL 400-047
  • +2 more
  • Birmingham, Alabama
  • +3 more
Oct 28, 2021

Neuroblastoma Recurrent Trial in Worldwide (Naxitamab and GM-CSF in combination with irinotecan and temozolomide)

Terminated
  • Neuroblastoma Recurrent
  • Naxitamab and GM-CSF in combination with irinotecan and temozolomide
  • Hong Kong, Hong Kong
  • +2 more
Nov 8, 2022

Alzheimer Trial in Aurora (Sargramostim, Saline - comparator)

Recruiting
  • Alzheimer Disease
  • Aurora, Colorado
    University of Colorado Anschutz Medical Campus
Jul 19, 2022

Neuroblastoma Trial in Worldwide (GM-CSF + Naxitamab)

Recruiting
  • Neuroblastoma
  • GM-CSF + Naxitamab
  • Gainesville, Florida
  • +22 more
Aug 29, 2022

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Radiotherapy
  • +4 more
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023

Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML) Trial run by the NHLBI

Completed
Has Results
  • Myelodysplastic Syndrome (MDS)
  • +2 more
  • WT1:126-134
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Jun 15, 2021

Hereditary Pulmonary Alveolar Proteinosis Trial in Cincinnati, Richmond (Leukine)

Completed
Has Results
  • Hereditary Pulmonary Alveolar Proteinosis
  • Cincinnati, Ohio
  • +1 more
Aug 31, 2020

HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor Trial in Seattle

Active, not recruiting
  • HER2-positive Breast Cancer
  • +8 more
  • pNGVL3-hICD vaccine
  • +6 more
  • Seattle, Washington
    Fred Hutchinson Cancer Research Center/University of Washington
Nov 1, 2022